Drug Type Antibody drug conjugate (ADC) |
Synonyms Mirzotamab clezutoclax, ABBV-155, ABBV155 |
Target |
Mechanism Bcl-xl inhibitors(Apoptosis regulator Bcl-X inhibitors), CD276 inhibitors(CD276 antigen inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC11H22N4O4 |
InChIKeyAGGWFDNPHKLBBV-YUMQZZPRSA-N |
CAS Registry159858-33-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | US | 13 Jul 2018 | |
Advanced Malignant Solid Neoplasm | Phase 1 | JP | 13 Jul 2018 | |
Advanced Malignant Solid Neoplasm | Phase 1 | AU | 13 Jul 2018 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CA | 13 Jul 2018 | |
Advanced Malignant Solid Neoplasm | Phase 1 | IL | 13 Jul 2018 | |
Advanced Malignant Solid Neoplasm | Phase 1 | NL | 13 Jul 2018 | |
Advanced Malignant Solid Neoplasm | Phase 1 | PR | 13 Jul 2018 | |
Advanced Malignant Solid Neoplasm | Phase 1 | KR | 13 Jul 2018 | |
Advanced Malignant Solid Neoplasm | Phase 1 | ES | 13 Jul 2018 | |
Advanced Malignant Solid Neoplasm | Phase 1 | TW | 13 Jul 2018 |
NCT03595059 (ASCO2023) Manual | Phase 1 | 78 | Mirzo-C (SCLC) | jqaqrboghz(wgiviqewkd) = vhghbqxull bklerktzvq (nlqvuyyiip ) View more | Positive | 31 May 2023 | |
Mirzo-C + docetaxel (NSCLC) | jqaqrboghz(wgiviqewkd) = oucoohbfzy bklerktzvq (nlqvuyyiip ) View more | ||||||
NCT03595059 (ASCO2021) Manual | Phase 1 | 59 | aghnrjzzjf(iinonixuiq) = There were no dose limiting toxicities (DLT) reported with monoTx. In comboTx, 2 pts experienced a DLT: Grade 4 neutrophil count decreased and Grade 3 lymphocyte count decreased considered related to paclitaxel. lfyynbbrdg (ixlxkcfcxg ) View more | Positive | 20 May 2021 | ||